S Kant Healthcare

Product category
  • Intermittent preventive treatment (sulfadoxine-pyrimethamine + amodiaquine)

Therapeutic indication
  • Seasonal Malaria chemoprevention (SMC) for children 3 to 59 months in eligible regions (Sahel region in Sub-Saharan Africa)

  • Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles for 4 months

  • 75% reduction in malaria episodes in pivotal trials

Key features
  • Recommended by WHO for the prevention of malaria in children in areas of high seasonal malaria transmission

  • 2-year shelf life

  • Drug distribution to healthy subjects mainly via door-to-door campaigns
  • WHO prequalification obtained in April 2021
  • 2nd taste-masked and dispersible SPAQ formulation prequalified by WHO
  • Registered in 6 countries; ongoing in 5 other countries
  • 18 million treatments delivered in 2021
Next milestone
  • Extension of the recommendation for children up to their 10th birthday
  • Validation of the dose and development of a specific packaging for children from 5 years old up until their 10th birthday
  • Exploration of expanded SMC coverage by adding a fifth monthly round of treatment in areas with longer seasonal transmission
  • Confirmation of potential efficacy and adoption in areas outside of the Sahel region
MMV Project Director
  • Dr André-Marie Tchouatieu